Verition Fund Management
NXTC icon

Verition Fund Management’s NextCure NXTC Stock Holding History

Verition Fund Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$466K Buy
+92,946
New +$517K ﹤0.01% 1635

Other funds holding NXTC

Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Verition Fund Management's NXTC Position: Q3 2026 in Review

Verition Fund Management opened a new position in NextCure (NXTC) in Q3 2026: 92,946 shares worth $466K. The stake represents ﹤0.01% of the portfolio and ranks #1635 among its holdings.

21 funds tracked by Wall St. Rank hold NXTC as of Q3 2026.

  • Verition Fund Management held 92,946 shares of NextCure worth $466K as of Q3 2026.
  • NextCure was a new Verition Fund Management position in Q3 2026.
  • NextCure made up ﹤0.01% of Verition Fund Management's portfolio in Q3 2026, its #1635 holding.
  • 21 funds tracked by Wall St. Rank held NextCure as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.